Drug Interactions means the occurrence when two or more drugs taken by a recipient lead to clinically significant toxicity that is characteristic of one or any of the drugs present or that leads to the interference with the effectiveness of one or any of the drugs.
Drug Interactions. May enhance the anticoagulant effect of anticoagulant/antiplatelet drugs eg aspirin, clopidogrel, non steroidal anti-Inflammatories (NSAIDs). (Refer to Summary of Product characteristics (SPC) for full list of drug interactions) Cost 2: 28 days supply of LMWH for prophylaxis of a patient (50-70kg) is: Enoxaparin £84.76; Dalteparin £79.04; Tinzaparin £99.82 References:
Drug Interactions. The pharmacodynamic effect of guanfacine can have an additive effect when taken with other products known to cause sedation, somnolence, syncope, hypotension or QT prolongation (e.g. alcohol, sedatives, hypnotics, benzodiazepines, barbiturates, antipsychotics). The concomitant use of guanfacine with QT prolonging medicinal products is not recommended. Co-administration with moderate and strong CYP3A4/5 inhibitors e.g. ciprofloxacin, macrolide antibiotics (e,g, erythromycin, clarithromycin), grapefruit juice, fluconazole and other azole antifungals elevate plasma guanfacine concentrations and increases the risk of adverse reactions such as hypotension, bradycardia, and sedation (decrease in dose of guanfacine is recommended). When patients are taking guanfacine concomitantly with a CYP3A4 inducer e.g. rifampicin, carbamazepine, phenytoin, phenobarbitone, some antiretrovirals, an increase in the dose of guanfacine within the recommended dose range is recommended. There is the possibility of additive CNS effects with valproic acid; consideration should be given to the monitoring of serum valproic acid concentrations. Adjustments in the dose of valproic acid and guanfacine may be necessary.
Examples of Drug Interactions in a sentence
Drug Interactions – Increases sedative effect of other CNS depressant drugs.
Drug Interactions – Tramadol (may cause seizures), Clonidine, cimetidine, sympathomimetics, valproic acid, warfarin, carbamazepine, bupropion, anticholinergics, quinolones.
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis.
Among the database titles are: Handbook of Adverse Drug Interactions, Rudolphs Pediatrics, Basic Clinical Pharmacology, and Dictionary of Medical Acronyms Abbreviations.
Drug Interactions (Drug-Drug, Drug-Food, Drug-Lab investigations) – types, interpretation and detection, prevention, Practice on market prescriptions, Use of drug interaction software’s.
More Definitions of Drug Interactions
Drug Interactions. (For a full list of interactions, please consult data sheets/SPC) Allopurinol inhibits metabolism of Azathioprine and increases risk of drug toxicity. Avoid concomitant use. Seek specialist’s advice BEFORE initiating Allopurinol, as dose of Azathioprine will need to be reduced. Warfarin. Azathioprine may possibly reduce the effect of warfarin. Febuxostat: co-prescription of azathioprine with febuxostat is not recommended by the manufacturer. References Prescribing and monitoring of DMARDs for inflammatory arthritis. Arthritis Research Council, 2005 xxxx://xxx.xxxxxxxxxxxxxxxxxxx.xxx/shop/products/publications/information-for-medical- professionals/hands-on/series-4/ho8.aspx BSR / BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy, 2017 Summary of Product Characteristics (SPC) of Azathioprine (Imuran ®) British National Formulary 68th edition, March 2015
Drug Interactions. (For a full list of interactions, please consult data sheets/SPC) Co-prescription of azathioprine may contribute to bone marrow toxicity. Sulfasalazine may reduce the absorption of digoxin.
Drug Interactions. There is an increased risk of ventricular arrhythmias when atomoxetine given with tricyclic antidepressants, amiodarone, antipsychotics that prolong the QT interval, disopyramide, parenteral erythromycin, mefloquine, methadone, moxifloxacin, sotalol; risk of ventricular arrhythmias with atomoxetine increased by diuretic induced hypokalaemia; atomoxetine should not be started until 2 weeks after stopping MAOIs, also MAOIs should not be started until at least 2 weeks after stopping atomoxetine ; possible increased risk of convulsions with antidepressants, buproprion, tramadol; metabolism of atomoxetine is possibly inhibited by fluoxetine, paroxetine; increased risk of cardiovascular side effects with intravenous salbutamol. Cost: At current prices (July 2017), one year’s treatment at 80 mg per day costs: £922
Drug Interactions. When given with CNS depressants (barbiturates, benzodiazepines, and opiods), more CNS depression is seen (increased sleepiness). (Wolters Kluwer Health, 2009) (Gehlbach & Xxxxx, 2005)
Drug Interactions. May enhance the anticoagulant effect of anticoagulant/antiplatelet drugs eg aspirin, clopidogrel, non steroidal anti-Inflammatories (NSAIDs). (Refer to Summary of Product characteristics (SPC) for full list of drug interactions)
Drug Interactions means the occurrence when two or more drugs
Drug Interactions. There is a risk of hypertensive crisis when methylphenidate given with MAOIs; avoid methylphenidate for at least 2 weeks after stopping MAOIs. There is an increased risk of hypertension when methylphenidate is given with volatile liquid general anaesthetics. Methylphenidate antagonises hypotensive effect of adrenergic neurone blockers; may enhance the anticoagulant effect of coumarins. The effects of methylphenidate may be enhanced by alcohol and may inhibit the metabolism of SSRIs (Selective Serotonin Reuptake Inhibitors) or tricyclic antidepressants. Serious adverse events have been reported with concomitant use of methylphenidate and clonidine (causality has not been established). It increases plasma concentration of phenytoin; may increase the plasma concentration of phenobarbital or primidone; may increase the side-effects of risperidone.